Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2

Introduction This phase 1 study assessed safety, maximum tolerated dose (MTD), pharmacokinetics, cerebrospinal fluid (CSF) distribution, and preliminary clinical activity of the receptor tyrosine kinase inhibitor TAK-285. Methods Patients with advanced, histologically confirmed solid tumors and East...

Descripción completa

Detalles Bibliográficos
Autores principales: LoRusso, Patricia, Venkatakrishnan, Karthik, Chiorean, E. Gabriela, Noe, Dennis, Wu, Jing-Tao, Sankoh, Serap, Corvez, Maria, Sausville, Edward A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913854/
https://www.ncbi.nlm.nih.gov/pubmed/23817974
http://dx.doi.org/10.1007/s10637-013-9988-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913854/
https://www.ncbi.nlm.nih.gov/pubmed/23817974
http://dx.doi.org/10.1007/s10637-013-9988-x

Ejemplares similares